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 Background: Long-term morbidity and mortality in liver transplant recipients is frequently secondary to immunosuppression 
toxicity. However, data are scarce regarding immunosuppression minimization in clinical practice.
 Material/Methods: In this cross-sectional, multicenter study, we reviewed the indications of immunosuppression minimization (de-
fined as tacrolimus levels below 5 ng/mL or cyclosporine levels below 50 ng/mL) among 661 liver transplant 
recipients, as well as associated factors and the effect on renal function.
 Results: Fifty-three percent of the patients received minimized immunosuppression. The median time from transplanta-
tion to minimization was 32 months. The most frequent indications were renal insufficiency (49%), cardiovas-
cular risk (19%), de novo malignancy (8%), and cardiovascular disease (7%). The factors associated with mini-
mization were older age at transplantation, longer post-transplant follow-up, pre-transplant diabetes mellitus 
and renal dysfunction, and the hospital where the patients were being followed. The patients who were min-
imized because of renal insufficiency had a significant improvement in renal function (decrease of the medi-
an serum creatinine level, from 1.50 to 1.34 mg/dL; P=0.004). Renal function significantly improved in patients 
minimized for other indications, too. In the long term, glomerular filtration rate significantly decreased in non-
minimized patients and remained stable in minimized patients.
 Conclusions: Immunosuppression minimization is frequently undertaken in long-term liver transplant recipients, mainly for 
renal insufficiency. Substantial variability exists regarding the use of IS minimization among centers.
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Background
Long-term survival after liver transplantation (LT) has increased 
in recent decades, due to refinements in surgical technique 
and postoperative care, along with the availability of better 
anti-infectious and immunosuppressive (IS) drugs. However, 
IS drugs cause morbidity and mortality in LT recipients. Long-
term mortality is mostly due to non-hepatic causes, and the 
risk of developing most of these non-hepatic conditions is in-
creased by IS drugs [1–4]. Furthermore, the availability of high-
ly efficacious drug combinations for the treatment of hepatitis 
C [5] will contribute to decreased deaths due to hepatic causes 
and reinforce the importance of non-hepatic causes of death.
IS minimization may overcome the adverse effects of IS 
drugs [6]. Many studies have evaluated the possibility of IS 
minimization, most of which have focused on the reduction 
or withdrawal of calcineurin inhibitors (CNI) in patients with 
nephrotoxicity [7,8]; however, the use of minimization in clin-
ical practice is unreported.
The aim of this study was to provide an overview of the use 
of minimization in Spain through a cross-sectional, multi-
center study. We also reviewed the indications of IS minimi-
zation and its effect on renal function. Our hypotheses were: 
a) that a high proportion of patients received minimized im-
munosuppression in the long term, b) that minimized patients 
had more co-morbidities than non-minimized patients, and c) 
that minimization benefitted these patients.
Material and Methods
We performed a cross-sectional study at 7 Spanish LT centers. 
From February 2014 to September 2014, approximately 100 
non-selected consecutive LT recipients attending their regular 
outpatient follow-up were included in each center.
The inclusion criteria were as follows: a) age greater 18 years; 
b) time since transplantation more than 12 months (with no 
maximum limit); c) absence of recent acute complications; and 
d) written informed consent. The exclusion criteria were as fol-
lows: a) transplantation of any non-hepatic organ; b) liver re-
transplantation; c) hospital admission in the last month; and 
d) current or recent (less than 3 months) treatment of hepa-
titis C with an interferon-containing regimen.
The following data were recorded:
–  Pre-LT data: demographic data, data about their liver dis-
ease and co-morbidities.
–  Data about current status: results of the most recent lab-
oratory tests, IS, and current information about graft func-
tion and co-morbidities.
–  Data about IS therapy and renal function during the first 
post-LT year.
– Data about IS minimization and its indication.
Definitions
–  IS minimization: steroid- and CNI-free IS or steroid-free and 
CNI-based IS, with tacrolimus levels below 5 ng/mL or cy-
closporine levels were below 50 ng/mL [9,10]. These results 
required confirmation on at least 3 occasions over a mini-
mum period of 6 months.
–  Arterial hypertension: blood pressure above 140/90 mmHg 
(130/80 in diabetics) [11] or the need for pharmacological 
therapy to adequately control blood pressure.
–  Diabetes: serum fasting glucose level above 126 mg/dL at 
least twice, or glycated hemoglobin above 6.5%, or serum 
glucose above 200 mg/dL 2 hours after an oral glucose tol-
erance test [12], or the need for anti-diabetic treatment.
–  Dyslipidemia: serum fasting cholesterol levels above 250 
mg/dL, or triglycerides above 150 mg/dL, or the need for 
pharmacological therapy.
–  Pre-transplant renal dysfunction: serum creatinine level 
above 1.5 mg/dL. After transplantation, the glomerular fil-
tration rate (GFR) was estimated using the MDRD4 formu-
la [13], and the renal disease stages were assessed accord-
ing to the chronic kidney disease (CKD) stages suggested by 
the NICE according to the GFR, expressed in mL/min/1.73 m2 
(stage 1: ³90; stage 2: 60–89; stage 3A: 45–59; stage 3B: 
30–44; stage 4: 15–29; stage 5 <15) [14].
–  Smoking: cumulative smoking greater than 10 pack-years 
(obtained by the product of the number of 20-cigarette packs 
smoked daily and the number of years of smoking).
Statistical analysis
Quantitative variables are expressed as the means (standard 
deviation) if they were normally distributed, or medians (in-
terquartile range) when they were not. Categorical variables 
are expressed as numbers (percentage). The following vari-
ables were studied as potentially associated with minimiza-
tion: transplantation center, time since transplantation, age 
sex, indication for transplantation (hepatitis C, alcoholic liver 
disease, hepatocellular carcinoma), MELD score at transplan-
tation, pre- and post-transplant renal dysfunction, arterial hy-
pertension, cardiovascular disease, smoking, and diabetes mel-
litus. Chi-squared and Mann-Whitney U tests were used for 
univariate analysis. Variables with P <0.2 in univariate analysis 
were entered into a multivariate logistic regression analysis. 
Differences between different measures of the same param-
eter were analyzed by the Friedman test and, if they differed 
significantly between 2 consecutive time points, were com-
pared using the Wilcoxon test.
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Values reaching a P value less than 0.05 were considered sta-
tistically significant. The statistical analysis was performed 
with the SPSS package version 22.0.
The study protocol was revised by the Spanish Drug Agency 
(AEMPS). The Institutional Review Boards from all the partici-
pating centers approved the protocol. All participants provid-
ed written informed consent.
Results
Description of the population
We recruited 661 patients. The number of patients recruited in 
each center ranged between 70 and 106. Their general char-
acteristics are presented in Table 1. Basal IS and its evolution 
are shown in Figures 1 and 2.
Whole group Minimized No-minimized
At the time of transplantation
Age (years)  54 (48–60)  56 (49–60.5)  51 (46–59)
Sex
 Male  475 (72%)  259 (73%)  216 (70%)
 Female  186 (28%)  94 (27%)  92 (30%)
Indication for transplantation
 Cirrhosis  619 (94%)  335 (95%)  284 (92%)
 Hepatocellular carcinoma  204 (31%)  118 (33%)  86 (28%)
 Alcoholic cirrhosis  330 (50%)  195 (55%)  135 (44%)
 Hepatitis C  172 (26%)  84 (24%)  88 (29%)
 MELD score  16 (13–20)  16 (12–20)  16 (13–19)
 Renal dysfunction  67 (10%)  46 (13%)  21 (7%)
 Arterial hypertension  109 (16%)  68 (19%)  41 (13%)
 Cardiovascular disease  37 (6%)  22 (6%)  15 (5%)
 Smoking  295 (45%)  168 (48%)  127 (41%)
 Diabetes mellitus  133 (20%)  84 (24%)  49 (16%)
At the time of study (most recent follow-up)
Time since transplantation (months)  101 (54–156)  107 (57–156)  91 (47–160)
Renal dysfunction  121 (18%)  87 (25%)  34 (11%)
Arterial hypertension  401 (61%)  227 (64%)  174 (56%)
Cardiovascular disease  118 (18%)  74 (21%)  44 (14%)
Smoking  103 (16%)  60 (17%)  43 (14%)
Diabetes mellitus  292 (44%)  162 (46%)  130 (42%)
Immunosuppression minimization  353 (53%)
Unsuccessful minimization  80 (12%)
Table 1. General characteristics of the 661 patients participating in the study.
Data are expressed as the median (inter-quartile range) or n (%).
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IS minimization
Minimized IS was received by 353 patients (53.4%). Their cur-
rent IS regimen is shown in Table 2. Comparison of the CNI lev-
els between minimized and non-minimized patients is shown 
in Figure 3. Eighty-nine of the IS-minimized patients (13.4% of 
the global series) were free of CNI. The median time from LT to 
minimization was 32 (14–66) months. The time between mini-
mization until the last follow-up in patients with minimized IS 
was 54 (25-99) months. The main indication for minimization 
was renal dysfunction (49.3%). Other frequent indications were 
high cardiovascular risk (19.3%), de novo malignancy (7.9%), 
cardiovascular disease (7.4%), and participation in a clinical 
trial (1.7%). Ninety-six patients (27.2% of minimized patients) 
were minimized without previous complications of IS thera-
py. The period between transplantation and minimization was 
shorter in patients with high cardiovascular risk (29 [12–56] 
months) and cardiovascular disease (36 [18–73] months) than 
in patients with renal dysfunction (43 [17–73] months), and 
de novo neoplasia (51 [24–66] months), and highest for pa-
tients in clinical trials (84 [27–101] months). Minimization was 
unsuccessfully attempted in 80 patients (12.1%) because of 
graft dysfunction.
Factors associated with minimization are shown in Tables 3 
and 4 (showing only variables included in multivariate anal-
ysis). Minimization was significantly more frequent in old-
er patients, and in patients with a longer post-transplant fol-
low-up, and with pre- and post-transplant renal dysfunction. 
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Figure 1.  Immunosuppressive drugs used by the 663 patients 
participating in the study (data expressed as 
percentages). MMF – mycophenolate mofetil; SRL/EVL 
– sirolimus or everolimus.
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Figure 2.  Evolution of the median levels of tacrolimus (A) and cyclosporine (B) in the 663 patients participating in the study.
Tacrolimus-based
 Tacrolimus monotherapy
 Tacrolimus + Azathioprine
 Tacrolimus + MMF
 Tacrolimus + mTORi
 Tacrolimus + MMF + mTORi
221
117
1
84
18
1
Cyclosporine-based
 Cyclosporine monotherapy
 Cyclosporine + MMF
 Cyclosporine + mTORi
43
18
22
3
Free of calcineurin inhibitors
 Azathioprine
 MMF
 mTORi
 MMF + mTORi
 Free of immunosuppression
89
1
52
13
6
17
Table 2.  Current immunosuppression regimen in 353 liver 
transplant patients with minimized immunosuppression.
MMF – mycophenolate mofetil;  mTORi – mammalian target of 
rapamycin inhibitors.
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Figure 3.  Comparison between the median levels of tacrolimus (A) and cyclosporine (B) levels in patients with minimized (triangles) 
versus non-minimized (circles) immunosuppression at the last follow-up.
Factor Percentage P
Hospital
 A
 B
 C
 D
 E
 F
 G
 48%
 70%
 53%
 55%
 64%
 49%
 35%
<0.001
Age at transplantation (years)*
 Minimization: 56 (49–60.5)
 No minimization: 51 (46-59)
<0.001
Time since transplantation (months)*
 Minimization: 107 (57–156)
 No minimization: 91 (47–160)
0.11
Hepatitis C
 Yes: 49%
 No: 55%
0.18
Alcoholic liver disease
 Yes: 59%
 No: 47%
0.004
Hepatocellular carcinoma
 Yes: 58%
 No: 51%
0.13
Smoking
 Yes: 57%
 No: 50%
0.12
Pre-transplant renal dysfunction
 Yes: 69%
 No: 52%
0.01
Pre-transplant arterial hypertension
 Yes: 62%
 No: 52%
0.046
Pre-transplant diabetes
 Yes: 63%
 No: 51%
0.015
Current renal dysfunction
 Yes: 72%
 No: 49%
<0.001
Current arterial hypertension
 Yes: 57%
 No: 48%
0.04
Cardiovascular complications
 Yes: 63%
 No: 51%
0.03
Table 3.  Factors associated with the minimization of immunosuppression (only variables entered into multivariate analysis; variables 
with P<0.2 are shown).
Data are expressed as the proportion of patients on minimized immunosuppression for those fulfilling/not fulfilling the factor, except * 
median (interquartile range).
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A hospital effect was also found: the proportion of patients 
with IS minimization was significantly higher in some centers. 
The proportion of minimized patients in each hospital ranged 
between 35.3% and 70.2%.
Evolution of renal function
The evolution of GFR and CKD stages are shown in Figures 4 and 
5. GFR decreased significantly after LT (Friedman test, P<0.001). 
Whereas this worsening of renal function was significant in 
the first 6 months; subsequent stabilization of renal func-
tion ensued 1 year after LT and at the most recent follow-up.
Renal function was compared among 3 different groups: pa-
tients without IS minimization, patients with minimization for 
renal dysfunction, and patients minimized for other causes. 
The evolution of GFR in these 3 groups is shown in Figure 6. 
Non-minimized patients had a significant decrease in the first 
6 months and between the end of the first year and the last 
follow-up (Figure 6A). In patients minimized for renal dysfunc-
tion, GFR decreased gradually until the first year, remaining 
stable at the last follow-up (Figure 6C); whereas in patients 
minimized for other reasons, GFR stabilized after initially wors-
ening and improved at the most recent follow-up (Figure 6B).
In patients who were minimized for renal dysfunction, the se-
rum creatinine levels significantly decreased from 1.5 (1.3–1.8) 
mg/dL before minimization to 1.3 (1.1–1.7) at the most recent 
follow-up (P=0.004). To evaluate whether both early and late 
minimization were equally followed by improved renal function, 
we compared 2 subgroups (according to the date of minimi-
zation before or after the median of 43 months since LT). The 
serum creatinine levels decreased both in patients minimized 
for renal dysfunction before 43 months (before minimization: 
1.4 (1.2–1.7) mg/dL; most recent: 1.3 [1.1–1.7] mg/dL; P=0.048) 
and in patients minimized after 43 months (before minimi-
zation: 1.5 [1.3–1.8] mg/dL; after minimization: 1.4 [1.1–1.8] 
mg/dL; P=0.02). The evolutions of the serum creatinine lev-
els and GFR in patients minimized for renal dysfunction be-
fore or after 43 months are shown in Supplementary figures 
1 and 2, respectively.
Factor OR (95% CI) P
Hospital
 A
 B
 C
 D
 E
 F
 G (reference)
 1.62 (0.88–3.02)
 5.63 (2.97–10.66)
 1.90 (0.95–3.82)
 2.81 (1.49–5.31)
 3.79 (1.98–7.26)
 1.90 (1.02–3.54)
 1
0.12
<0.001
0.07
0.001
<0.001
0.04
Age at LT (years)  1.024 (1.004–1.044) 0.017
Time since transplantation (months)  1.004 (1.001–1.007) 0.009
Hepatitis C  0.96 (0.64–1.43) 0.83
Alcoholic cirrhosis  1.31 (0.88–1.95) 0.16
HCC  1.31 (0.88–1.95) 0.18
Smoking  1.06 (0.77–1.53) 0.76
Pre-transplant renal dysfunction  2.27 (1.23–4.18) 0.009
Pre-transplant arterial hypertension  1.19 (0.72–1.96) 0.51
Pre-transplant diabetes  1.30 (0.77–2.18) 0.32
Current renal dysfunction  2.70 (1.63–4.44) <0.001
Current arterial hypertension  0.93 (0.63–1.37) 0.72
Cardiovascular complications  1.04 (0.65–1.67) 0.87
Table 4. Factors associated with the minimization of immunosuppression (multivariate analysis).
OR (95% CI) – odds ratio with 95% confidence interval; HCC – hepatocellular carcinoma.
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Figure 4.  Evolution of the glomerular filtration rate (GFR) of 
the 663 patients participating in the study. Data 
are expressed as the median (interquartile range). 
Differences between 2 consecutive time points are 
expressed by the following annotation: *** P<0.001.
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Figure 5.  Evolution of the renal function of the 661 patients 
participating in the study according to the stages of 
chronic kidney disease (CKD).
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Figure 6.  Evolution of glomerular filtration rate (GFR) of the patients with non-minimized immunosuppression (A), patients with 
minimized immunosuppression for non-renal causes (B) and patients minimized for renal dysfunction (C). Data are 
expressed as the median (interquartile range). Differences between 2 consecutive time points are expressed by the following 
annotations: * P value between 0.5 and 0.01; ** P value between 0.01 and 0.001; *** P<0.001.
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Calcineurin inhibitor-free patients
Eighty-nine patients (13.4% of the whole series) were free 
of CNI. Most of them were receiving MMF (52) or an mTORi 
(Table 2). Their median age was 57 (50.5–60.5) years and they 
had been transplanted a median of 127 (84–178.5) months 
prior. The main indications for minimization in these patients 
were renal dysfunction (58.4%), cardiovascular risk (26.9%), 
de novo neoplasia (13.5%), cardiovascular disease (6.7%), and 
participation in a clinical trial (3.3%). Seven patients were free 
of CNI without previous complications of IS therapy.
Substantial variability was observed in the proportion of pa-
tients that were free of CNI among the 7 centers: although 
the median was 14%, it ranged between 1% and 36%. No 
correlation was observed between the proportion of mini-
mized patients in each hospital and the proportion of pa-
tients free of CNI.
As in the global minimization group, CNI withdrawal was fol-
lowed by a significant improvement in renal function. The se-
rum creatinine levels decreased from 1.6 (1.4–1.8) mg/dL be-
fore minimization to 1.3 (1.1–1.6) mg/dL at the last follow-up 
(P=0.002).
Discussion
Whereas CNI are the cornerstone of IS in all solid organ trans-
plant programs, they are also responsible for much of the 
long-term morbidity and mortality. They cause dose-depen-
dent nephrotoxicity [15], with high CNI exposure increasing 
the risk of de novo malignancy [16,17] or recurrent hepato-
cellular carcinoma [18,19]. Thus, the reduction or withdraw-
al of CNI may theoretically reduce the risk of most IS-related 
complications. In this study, we examined the IS minimiza-
tion frequency in the real world. Thus, it reflects the status of 
IS in different hospitals with different IS protocols that have 
evolved over the years.
We found that more than 50% of unselected LT recipients were 
receiving an IS regimen with tacrolimus levels below 5 ng/mL, 
cyclosporine levels below 50 ng/mL or without any calcineu-
rin inhibitor at a median of 32 months after LT. This finding 
contrasts with the maintenance IS used in other solid organ 
transplant recipients. For example, in a recent multicenter 
French trial of IS minimization in renal transplant recipients, 
the mean cyclosporine levels were above 100 ng/mL [20]. The 
proportion of patients receiving minimized IS was comparable 
to that in other series of LT [9], and higher than that in other 
series [10]. In the present study, the minimized IS proportion 
also varied among different centers, ranging from 35% to 70%. 
In fact, as this was a retrospective study, the center where the 
patients were followed was independently related to a higher 
proportion of minimization, and more than one-quarter of the 
patients were minimized without any previous complication 
of IS. When we analyzed the proportion of patients in whom 
minimization was attempted (successfully or unsuccessfully), 
the proportion ranged between 43% and 93% (median 66%). 
Thus, although minimization is attempted in most patients, a 
substantial range was observed among the different institu-
tions. Another noteworthy finding was that more than 10% 
of the patients were free of CNI, despite the wide variability 
in these data. The proportion of patients free of CNI reached 
36% in one of the centers participating in the study.
In this series, the most frequent indication for IS minimization 
was renal dysfunction. Minimization was followed by a signifi-
cant improvement in renal function in patients who were min-
imized because of renal dysfunction. Long-term improvement 
of renal function was also found in patients minimized for oth-
er indications, whereas non-minimized patients experienced a 
decrease in GFR in the long-term. This finding suggests that IS 
minimization may help preserve renal function, including in pa-
tients lacking notable renal dysfunction, whereas a maintained 
standard IS leads to gradual worsening of renal function. This 
beneficial effect of minimizing (or even withdrawing) CNI has 
been found previously in other studies [21–25]. In the present 
study, the beneficial effect of minimization was evident both 
in patients minimized early and late; however, early interven-
tion appears more effective in preserving renal function after 
LT [24]. Thus, early detection and intervention has been sug-
gested regarding the progressive deterioration of renal func-
tion [26]. In this study, although renal function was worse in 
patients with minimized IS, the differences in the CNI levels 
during the first post-LT year were small. This finding suggests 
that in actual practice, IS minimization is usually delayed.
The second main indication for IS minimization was cardio-
vascular complications or a high risk thereof. The proportion 
of patients with risk factors for cardiovascular complications 
was high: 61% had arterial hypertension, 44% had diabe-
tes mellitus, and more than 15% were smokers and had re-
nal dysfunction. Consequently, 18% of the patients had car-
diovascular complications. Because these cardiovascular risk 
factors are related to IS, changes in IS could be introduced to 
improve this risk profile. Steroid-free immunosuppression is 
associated with a lower proportion of diabetes mellitus and 
lower cholesterol levels [27]. Reducing or withdrawing CNI has 
been associated not only with improvement in renal function 
but also with better control of arterial hypertension, dyslipid-
emia, and diabetes mellitus [7,22,28,29]. However, the poten-
tial effect of IS minimization was not analyzed in this study. 
Accordingly, older patients and patients with diabetes melli-
tus accounted for a significant proportion of those who un-
derwent IS minimization.
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CNI were successfully minimized in more than 50% of the pa-
tients, although minimization was not always possible. Eighty 
patients (12%) could not achieve IS minimization. This pro-
portion is similar to that in previous studies [7,8,30]. Hence, 
the potential benefit of IS minimization should be balanced by 
the potential risk of rejection. Not all LT recipients can expe-
rience the potential benefits of IS minimization. Interestingly, 
the proportion of patients in whom minimization was unsuc-
cessfully attempted ranged between 2% and 29% among the 
7 institutions participating in this study.
The optimal IS minimization strategy requires further investi-
gation. In a recently published systematic review of renal trans-
plantation, the combination of low-dose CNI and mycopheno-
lic acid formulations resulted in improved renal function and 
reduced risk of harm [31]. Conversion, withdrawal and avoid-
ance of CNI were associated with fewer benefits and great-
er harms. Considering that LT has an immunological privilege 
over kidney transplantation, this finding may not be true for LT.
The main limitation of this study is its retrospective nature: 
our study shows that a large proportion of patients maintain 
adequate graft function; however, the proportion of patients 
who develop rejection on minimized IS is unknown. Whereas IS 
minimization was unsuccessfully attempted in 12% of the pa-
tients in the present series, some patients who may have died 
or lost their grafts would not have been detected because of 
the study design. By contrast, patients who might have been 
minimized successfully may have died before minimization was 
attempted because such patients tend to have more morbid-
ities. Rather than attempting to evaluate a single minimiza-
tion protocol, this study instead examined the use of minimi-
zation in a large cohort of patients.
Conclusions
More than 50% of LT recipients can achieve IS minimization in 
the long-term. The proportion of patients who could undergo 
minimization or perhaps CNI withdrawal might be higher, be-
cause the proportion of IS-minimized patients differs widely 
among hospitals. The main indication for IS minimization is 
renal dysfunction, and minimization may improve renal func-
tion. The potential benefits of IS minimization should be ex-
plored in future prospective trials, comparing the outcomes 
of patients who undergo minimization with the evolution of 
patients who maintain standard IS.
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Supplementary Figure 1.  Evolution of the serum creatinine levels of the patients minimized for renal dysfunction after (A) or before 
(B) 43 months after transplantation. Data are expressed as the median (interquartile range). Differences 
between 2 consecutive time points are expressed by the following annotations: * P value between 0.5 and 
0.01; ** P value between 0.01 and 0.001; *** P<0.001.
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Supplementary Figure 2.  Evolution of the glomerular filtration rate of the patients minimized for renal dysfunction after (A) or before 
(B) 43 months after transplantation. Data are expressed as the median (interquartile range). Differences 
between 2 consecutive time points are expressed by the following annotations: * P value between 0.5 and 
0.01; ** P value between 0.01 and 0.001; *** P<0.001.
References:
 1. Gelson W, Hoare M, Dawwas MF et al: The pattern of late mortality in liv-
er transplant recipients in the United Kingdom. Transplantation, 2011; 91: 
1240–44
 2. Rubin A, Sánchez-Montes C, Aguilera V et al: Long-term outcome of “long-
term liver transplant survivors”. Transpl Int, 2013; 26: 740–50
 3. Schoening WN, Buescher N, Rademacher S et al: Twenty-year longitudinal 
follow-up after orthotopic liver transplantation: A single-center experience 
of 313 consecutive cases. Am J Transplant, 2013; 13: 2384–94
 4. Watt KD, Pedersen RA, Kremers WK et al: Evolution of causes and risk fac-
tors for mortality post-liver transplant: results of the NIDDK long-term fol-
low-up study. Am J Transplant, 2010; 10: 1420–27
 5. Brown RS, O’Leary JG, Reddy KR et al: Interferon-free therapy for genotype 
1 hepatitis C in liver transplant recipients: Real-world experience from the 
hepatitis C therapeutic registry and research network. Liver Transpl, 2016; 
22: 24–33
 6. Londoño M-C, Rimola A, O’Grady J, Sanchez-Fueyo A: Immunosuppression 
minimization vs. complete drug withdrawal in liver transplantation. J Hepatol, 
2013; 59: 872–79
 7. Herrero JI, Quiroga J, Sangro B et al: Conversion of liver transplant recipi-
ents on cyclosporine with renal impairment to mycophenolate mofetil. Liver 
Transpl Surg, 1999; 5: 414–20
 8. Planas J, Martinez V, Gonzalez E et al: Mycophenolate mofetil can be used 
as monotherapy late after liver transplantation. Am J Transplant, 2004; 4: 
1650–55
 9. Barbier L, Garcia S, Cros J et al: Assessment of chronic rejection in liver graft 
recipients receiving immunosuppression with low-dose calcineurin inhibi-
tors. J Hepatol, 2013; 59: 1223–30
 10. Martínez-Saldivar B, Prieto J, Berenguer M et al: Control of blood pressure 
in liver transplant recipients. Transplantation, 2012; 93: 1031–37
 11. Mancia G, De Backer G, Dominiczak A et al: 2007 Guidelines for the 
Management of Arterial Hypertension: The Task Force for the Management 
of Arterial Hypertension of the European Society of Hypertension (ESH) and 
of the European Society of Cardiology (ESC). J Hypertens, 2007; 25: 1105–87
 12. American Diabetes Association: Classification and diagnosis of diabetes. 
Diabetes Care, 2015; 38(Suppl,): S8
 13. Levey AS, Bosch JP, Lewis JB et al: A more accurate method to estimate glo-
merular filtration rate from serum creatinine: A new prediction equation. 
Modification of Diet in Renal Disease Study Group. Ann Intern Med, 1999; 
130: 461–70
 14. Crowe E, Halpin D, Stevens P: Early identification and management of chron-
ic kidney disease: Summary of NICE guidance. BMJ, 2008; 337: a1530
 15. Gonwa TA, Mai ML, Melton LB et al: End-stage renal disease (ESRD) after 
orthotopic liver transplantation (OLTX) using calcineurin-based immuno-
therapy: risk of development and treatment. Transplantation, 2001; 72: 
1934–39
 16. Dantal J, Hourmant M, Cantarovich D et al: Effect of long-term immunosup-
pression in kidney-graft recipients on cancer incidence: Randomised com-
parison of two cyclosporin regimens. Lancet, 1998; 351: 623–28
 17. Carenco C, Assenat E, Faure S et al: Tacrolimus and the risk of solid cancers 
after liver transplant: a dose effect relationship. Am J Transplant, 2015; 15: 
678–86
 18. Rodríguez-Perálvarez M, Tsochatzis E, Naveas M et al: Reduced exposure to 
calcineurin inhibitors early after liver transplantation prevents recurrence 
of hepatocellular carcinoma. J Hepatol, 2013; 59: 1193–99
 19. Vivarelli M, Cucchetti A, Piscaglia F et al: Analysis of risk factors for tumor 
recurrence after liver transplantation for hepatocellular carcinoma: Key role 
of immunosuppression. Liver Transpl, 2005; 11: 497–503
 20. Thierry A, Lemeur Y, Ecotière L et al: Minimization of maintenance immu-
nosuppressive therapy after renal transplantation comparing cyclosporine 
A/azathioprine or cyclosporine A/mycophenolate mofetil bitherapy to cy-
closporine A monotherapy: a 10-year postrandomization follow-up study. 
Transpl Int, 2016; 29: 23–33
 21. Pageaux G-PP, Rostaing L, Calmus Y et al: Mycophenolate mofetil in com-
bination with reduction of calcineurin inhibitors for chronic renal dysfunc-
tion after liver transplantation. Liver Transpl, 2006; 12: 1755–60
 22. Orlando G, Baiocchi L, Cardillo A et al: Switch to 1.5 grams MMF monother-
apy for CNI-related toxicity in liver transplantation is safe and improves re-
nal function, dyslipidemia, and hypertension. Liver Transpl, 2007; 13: 46–54
 23. Saliba F, Simone DP, Nevens F et al: Renal function at two years in liver 
transplant patients receiving everolimus: Results of a randomized, multi-
center study. Am J Transplant, 2013; 13: 1734–45
 24. Neuberger JM, Mamelok RD, Neuhaus P et al: Delayed introduction of re-
duced-dose tacrolimus, and renal function in liver transplantation: The 
‘ReSpECT’ Study. Am J Transplant, 2009; 9: 327–36
 25. Pons JA, Ramírez P, Revilla-Nuin B et al: Immunosuppression withdrawal 
improves long-term metabolic parameters, cardiovascular risk factors and 
renal function in liver transplant patients. Clin Transplant, 2009; 23: 329–36
 26. Castells L, Baliellas C, Bilbao I et al: Detección precoz, prevención y manejo 
de la insuficiencia renal en el trasplante hepático. Gastroenterol Hepatol, 
2014; 37: 480–91 [in Spain]
 27. Sgourakis G, Dedemadi G: Corticosteroid-free immunosuppression in liver 
transplantation: An evidence-based review. World J Gastroenterol, 2014; 
20: 10703–14
274
Aguiar D. et al.: 
Minimization of IS in LT
© Ann Transplant, 2017; 22: 265-275
ORIGINAL PAPER
Indexed in: [Science Citation Index Expanded] [Index Medicus/MEDLINE] 
[Chemical Abstracts] [Scopus]
 28. Cicinnati VR, Z Yu, Klein CG et al: Clinical trial: switch to combined my-
cophenolate mofetil and minimal dose calcineurin inhibitor in stable liv-
er transplant patients – assessment of renal and allograft function, car-
diovascular risk factors and immune monitoring. Aliment Pharmacol Ther, 
2007; 26: 1195–208
 29. Herrero JI, Quiroga J, Sangro B et al: Conversion from calcineurin inhibitors 
to mycophenolate mofetil in liver transplant recipients with diabetes mel-
litus. Transplant Proc, 2003; 35: 1877–79
 30. Abdelmalek MF, Humar A, Stickel F et al: Sirolimus conversion regimen ver-
sus continued calcineurin inhibitors in liver allograft recipients: A random-
ized trial. Am J Transplant, 2012; 12: 694–705
 31. Sawinski D, Trofe-Clark J, Leas B et al: Calcineurin inhibitor minimization, 
conversion, withdrawal, and avoidance strategies in renal transplantation: 
A systematic review and meta-analysis. Am J Transplant, 2016; 16: 2117–38
275
Aguiar D. et al.: 
Minimization of IS in LT
© Ann Transplant, 2017; 22: 265-275
ORIGINAL PAPER
Indexed in: [Science Citation Index Expanded] [Index Medicus/MEDLINE] 
[Chemical Abstracts] [Scopus]
